Table 5:
tGSS to infer adherence to current regimens and to predict response to subsequent regimens.
| Characteristics of all viremic participants (n=160) |
1st line regimen | 2nd line regimen |
|---|---|---|
| n=112(70%) | n=48(30%) | |
| Current regimens tGSS | ||
| tGSS≤2 | 104(93%) | 6(12.5%) |
| tGSS>2 | 8(7%) | 42(87.5%) |
| Predicted subsequent regimens as per the Zimbabwe national ART Guidelines | ||
| tGSS≤2 | 12 (11%) | 0(0%) |
| tGSS>2 | 100(89%) | 48(100%) |
| Estimated TLD susceptibility as a subsequent regimen per WHO guidelines | ||
| tGSS≤2 | 47(42%) | 4(8%) |
| tGSS>2 | 65(58%) | 44(92%) |
| Estimated TLD by substituting AZT for TDF as subsequent regimens | ||
| tGSS≤2 | 5(4%) | 0(0%) |
| tGSS>2 | 107(96%) | 48(100%) |
| Susceptibility to doravirine | ||
| GSS=1 | 112(100%) | 48(100%) |
| Susceptibility to etravirine | ||
| GSS=1 | 52(46%) | 31(65%) |
| Susceptibility to rilpivirine | ||
| GSS=1 | 32(29%) | 24(50%) |
tGSS total genotypic susceptibility score, ART antiretroviral therapy; TLD tenofovir/lamivudine/dolutegravir; WHO World Health Organization; AZT zidovudine; TDF tenofovir; GSS genotypic susceptibility score; The preferred 2nd line regimens for adolescents (>=10 years) and adults as per the Zimbabwe national ART guidelines is AZT+3TC+ATV/r or LPV/r (if TDF was used in 1st line ART) and TDF+3TC+ATV/r or LPV/r (if AZT was used in 1st line ART). The preferred 3rd line treatment is darunavir/ritonavir (DRV/r) + raltegravir/dolutegravir +2 optimized NRTIs.